# Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women

> **NCT01829919** · PHASE1 · COMPLETED · sponsor: **Noven Therapeutics** · enrollment: 24 (actual)

## Conditions studied

- Postmenopausal Symptoms

## Interventions

- **DRUG:** Brisdelle (paroxetine mesylate)

## Key facts

- **NCT ID:** NCT01829919
- **Lead sponsor:** Noven Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01829919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01829919, "Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01829919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*